Incannex Healthcare Approves 1-for-30 Reverse Stock Split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IXHL?
Incannex Healthcare announced that the board of directors of the Company approved a 1-for-30 reverse stock split of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on May 27, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 26, 2026. The Company's common stock will open for trading under a new CUSIP number 45333F 208 on The Nasdaq Capital Market on February 27, 2026, on a split-adjusted basis under the current ticker symbol "IXHL." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on Nasdaq.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IXHL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IXHL
About IXHL
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Incannex Healthcare to Implement 1-for-30 Reverse Stock Split
- Reverse Stock Split Announcement: Incannex Healthcare has announced a 1-for-30 reverse stock split effective February 26, 2026, aimed at increasing its per-share trading price to comply with Nasdaq's minimum bid price requirement for continued listing.
- Share Count Reduction: The reverse split will reduce the outstanding shares from approximately 358.3 million as of February 20, 2026, to about 11.9 million, while the total authorized share count will remain unchanged, significantly enhancing the per-share value.
- Trading Timeline: The split-adjusted shares are expected to begin trading on the Nasdaq Capital Market on February 27, 2026, under the existing ticker symbol “IXHL,” which may help boost market visibility and investor interest in the company.
- Market Reaction: Following the announcement of the reverse split, IXHL's stock price fell by 37.73% to $0.1706, indicating market concerns regarding the company's current financial health, which could impact investor confidence.
See More
Incannex Healthcare Announces 1-for-30 Reverse Stock Split
- Reverse Split Decision: Incannex Healthcare's board approved a 1-for-30 reverse stock split, previously sanctioned by shareholders on May 27, 2025, aimed at boosting share price to meet Nasdaq listing requirements.
- Legal Effect Timing: The reverse split will take legal effect at 4:01 p.m. ET on February 26, 2026, which is expected to impact the company's stock liquidity and potentially attract more investor interest.
- Trading Change Notification: Following the reverse split, Incannex common shares will begin trading on the Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’, ensuring easy identification for investors.
- Stock Price Reaction: Following the announcement of the reverse split, Incannex stock tumbled over 32% on Wednesday morning, reflecting a negative market reaction to the decision that could affect the company's future financing capabilities and market confidence.
See More
Incannex Approves 1-for-30 Reverse Stock Split
- Reverse Split Approval: Incannex Healthcare Inc.'s board has approved a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring the company's continued listing on the exchange.
- Shareholder Meeting Endorsement: The reverse split plan was approved at a special shareholder meeting on May 27, 2025, and is set to take effect at 4:01 PM ET on February 26, 2026, marking a significant adjustment in the company's capital market strategy.
- Change in Share Count: Post-split, the number of outstanding shares will decrease from approximately 358,329,368 to about 11,944,313, while the total authorized shares will remain unchanged, impacting the ownership structure of the company.
- Shareholder Rights Protection: For shareholders holding fractional shares, the reverse split will automatically adjust their holdings to whole shares, ensuring that no shareholder suffers a loss due to the split ratio, reflecting the company's commitment to protecting shareholder interests.
See More
INCANNEX HEALTHCARE INC - AUTHORIZES 1-FOR-30 REVERSE STOCK SPLIT
- Company Announcement: Incannex Healthcare has approved a 1-for-30 reverse stock split.
- Impact on Shares: The reverse stock split is intended to increase the company's share price and improve its marketability.
See More
INCANNEX DECLARES REVERSE STOCK SPLIT
Announcement of Reverse Stock Split: Incannex Healthcare has announced a reverse stock split to consolidate its shares, aimed at increasing the share price and improving market perception.
Rationale Behind the Decision: The reverse stock split is intended to enhance the company's ability to attract institutional investors and comply with stock exchange listing requirements.
Impact on Shareholders: Shareholders will see their number of shares reduced, but the overall value of their holdings should remain the same post-split.
Future Plans: The company plans to use the improved share price to facilitate future capital raising efforts and support its growth strategy.
See More
Incannex Secures FDA Fast Track Designation for IHL-42X in OSA Treatment
- Fast Track Designation: Incannex Healthcare's IHL-42X oral fixed-dose combination drug has received FDA Fast Track designation, supporting its potential in treating obstructive sleep apnea (OSA) and marking a significant advancement for the company in clinical stages.
- Clinical Trial Results: In three clinical trials, IHL-42X demonstrated promising safety and efficacy, with individual reductions in the Apnea-Hypopnea Index (AHI) of up to 83%, which not only enhances patient quality of life but also establishes a strong foundation for the company's future market competitiveness.
- Enhanced Regulatory Interaction: With the Fast Track designation, Incannex will benefit from more frequent structured interactions with the FDA to discuss clinical strategies and data requirements, which will expedite the new drug application process and increase the likelihood of market access.
- Significant Market Potential: OSA affects millions globally, and with no approved oral pharmacotherapy currently available, the successful development of IHL-42X will fill this market gap, potentially providing substantial commercial opportunities and long-term growth for the company.
See More
Incannex Healthcare to Implement 1-for-30 Reverse Stock Split
- Reverse Stock Split Announcement: Incannex Healthcare has announced a 1-for-30 reverse stock split effective February 26, 2026, aimed at increasing its per-share trading price to comply with Nasdaq's minimum bid price requirement for continued listing.
- Share Count Reduction: The reverse split will reduce the outstanding shares from approximately 358.3 million as of February 20, 2026, to about 11.9 million, while the total authorized share count will remain unchanged, significantly enhancing the per-share value.
- Trading Timeline: The split-adjusted shares are expected to begin trading on the Nasdaq Capital Market on February 27, 2026, under the existing ticker symbol “IXHL,” which may help boost market visibility and investor interest in the company.
- Market Reaction: Following the announcement of the reverse split, IXHL's stock price fell by 37.73% to $0.1706, indicating market concerns regarding the company's current financial health, which could impact investor confidence.
See More
Incannex Healthcare Announces 1-for-30 Reverse Stock Split
- Reverse Split Decision: Incannex Healthcare's board approved a 1-for-30 reverse stock split, previously sanctioned by shareholders on May 27, 2025, aimed at boosting share price to meet Nasdaq listing requirements.
- Legal Effect Timing: The reverse split will take legal effect at 4:01 p.m. ET on February 26, 2026, which is expected to impact the company's stock liquidity and potentially attract more investor interest.
- Trading Change Notification: Following the reverse split, Incannex common shares will begin trading on the Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’, ensuring easy identification for investors.
- Stock Price Reaction: Following the announcement of the reverse split, Incannex stock tumbled over 32% on Wednesday morning, reflecting a negative market reaction to the decision that could affect the company's future financing capabilities and market confidence.
See More
Incannex Approves 1-for-30 Reverse Stock Split
- Reverse Split Approval: Incannex Healthcare Inc.'s board has approved a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring the company's continued listing on the exchange.
- Shareholder Meeting Endorsement: The reverse split plan was approved at a special shareholder meeting on May 27, 2025, and is set to take effect at 4:01 PM ET on February 26, 2026, marking a significant adjustment in the company's capital market strategy.
- Change in Share Count: Post-split, the number of outstanding shares will decrease from approximately 358,329,368 to about 11,944,313, while the total authorized shares will remain unchanged, impacting the ownership structure of the company.
- Shareholder Rights Protection: For shareholders holding fractional shares, the reverse split will automatically adjust their holdings to whole shares, ensuring that no shareholder suffers a loss due to the split ratio, reflecting the company's commitment to protecting shareholder interests.
See More
INCANNEX HEALTHCARE INC - AUTHORIZES 1-FOR-30 REVERSE STOCK SPLIT
- Company Announcement: Incannex Healthcare has approved a 1-for-30 reverse stock split.
- Impact on Shares: The reverse stock split is intended to increase the company's share price and improve its marketability.
See More
INCANNEX DECLARES REVERSE STOCK SPLIT
Announcement of Reverse Stock Split: Incannex Healthcare has announced a reverse stock split to consolidate its shares, aimed at increasing the share price and improving market perception.
Rationale Behind the Decision: The reverse stock split is intended to enhance the company's ability to attract institutional investors and comply with stock exchange listing requirements.
Impact on Shareholders: Shareholders will see their number of shares reduced, but the overall value of their holdings should remain the same post-split.
Future Plans: The company plans to use the improved share price to facilitate future capital raising efforts and support its growth strategy.
See More
Incannex Secures FDA Fast Track Designation for IHL-42X in OSA Treatment
- Fast Track Designation: Incannex Healthcare's IHL-42X oral fixed-dose combination drug has received FDA Fast Track designation, supporting its potential in treating obstructive sleep apnea (OSA) and marking a significant advancement for the company in clinical stages.
- Clinical Trial Results: In three clinical trials, IHL-42X demonstrated promising safety and efficacy, with individual reductions in the Apnea-Hypopnea Index (AHI) of up to 83%, which not only enhances patient quality of life but also establishes a strong foundation for the company's future market competitiveness.
- Enhanced Regulatory Interaction: With the Fast Track designation, Incannex will benefit from more frequent structured interactions with the FDA to discuss clinical strategies and data requirements, which will expedite the new drug application process and increase the likelihood of market access.
- Significant Market Potential: OSA affects millions globally, and with no approved oral pharmacotherapy currently available, the successful development of IHL-42X will fill this market gap, potentially providing substantial commercial opportunities and long-term growth for the company.
See More
